Introduction
Primary lung cancer (PLC) is one of the most malignant tumors with the highest incidence and mortality rate in the world. And PLC has been classified historically into two clinically relevant groups: small cell lung cancer (SCLC) and non-small cell lung cancer NSCLC (1) . More than 80% of lung cancer patients are affected by NSCLC, while the remaining 20% by SCLC (2) . There were approximately 226,160 new cancer cases and 160,340 deaths of lung cancer by United States,
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2012 (3) . NSCLC is the leading cause of lung cancer-related mortality world-wide and the 5-year survival rate for it is among the lowest of all cancers (approximately 15%) (4) . This is largely attributed to the diagnosis at late stage. As early detection as IA stage of lung cancer can raise the 5-year survival to 80%, comparing to 15% of overall NSCLC (5) . So far, the gold standard of diagnosing NSCLC is also pathology. However, biopsy can be associated with significant expense, manpower issues and risk of patient injury. Moreover, it couldn't screen cancer at early stage. Usually, some ongoing diagnostic tools at clinics include computerized tomography (CT) scans, bronchoscope and sputum analysis, none of which turns out to be effective in early diagnosis of NSCLC.
Proteomics provided a new way to diagnose cancers and an evaluation tool through the analyses of changes in cancer biomarkers. As one of the new tools of proteomics research to diagnose NSCLC, SELDI-TOF-MS relies on differential protein expression profiling, and the fundamental approach is based on the assumption that the pathology of concern will affect some physiological processes causing changes in the protein expression levels (6) . It has the advantages of being a high-throughput technique for analyzing complex biological specimens such as serum and the ability to detect changes in multiple proteins simultaneously with high sensitivity and specificity (7) . It analyses small volumes of clinical samples without destroying the proteins to be detected and is capable of examining proteins and peptides, which are not available for conventional methods (6) . At present, there are many exciting SELDI applications, which have been described by numerous laboratories, especially in studying cancers of various organs, including prostate (8) , liver (9), pancreas (10), ovary (11), breast (12), lung (13) , colon (14) , and others (15, 16 
Materials and Methods

Search Strategy and Study Selection
We conducted a comprehensive literature search to identify studies that evaluated the diagnostic accuracy of The following search strategy was adopted: ("SELDI-TOF-MS" or "surface enhanced laser desorption/ionization time of flight mass spectrometry" or "laser desorption-ionization mass spectrometry" or "mass spectrometry" or "matrix-assisted laser desorption-ionization") and ("lung cancer" or "lung neoplasms" or "lung carcinoma" or "cancer of lung" or "pulmonary cancer" or "non-small cell lung cancer" or "NSCLC" or "nonsmall cell lung carcinoma"). Duplicate articles identified in both medline and EMBASE were manually deleted using Reference Manager (Thomson Reuters EndNote X5). Results were arbitrated by two investigators (Feng Jiang and Xiang-Yu Zhou), on the basis of the title and abstract, and the full paper of each potentially eligible study was then obtained. For further relevant studies, we checked the reference lists of identified trials.
Eligible Criteria
All studies that reported data on patients with a confirmed diagnosis of NSCLC and compared the measurement of SELDI-TOF-MS with pathology standard were considered for inclusion. Only studies that reported sufficient data to allow construction of 2 3 2 tables were included. Irrelative studies were excluded such as animal studies. Within the studies evaluated, those with endpoints that were not comparable were excluded.
Quality Assessment
Two independent reviewers (Feng Jiang and Xiang-Yu Zhou) used the quality assessment of studies of diagnostic accuracy included in systematic reviews (QUADAS) instrument (18) to assess the quality of selected articles (Table I) . Any disagreements were resolved by discussion and consensus, if necessary after contacting the authors for clarification. Study quality was assessed using the QUADAS-list, with each item scored as "yes", "no", or "unclear". We did not calculate summary scores of quality because the interpretation was problematic and potentially misleading (19) .
Data Extraction and Analysis
Data were extracted by one reviewer (Feng Jiang) and checked by another (Xiang-Yu Zhou). The data-extraction form was accompanied by a background document that stated how each item on the form should be interpreted. All data collection were performed according to a protocol with the following information being extracted from each study: first author, year of publication, population characteristics, study design, inclusion and exclusion criteria, number of subjects, as well as the method of determination of NSCLC.
The primary endpoints were sensitivity, specificity, positive and negative predictive values of serum proteome profiles with SELDI-TOF-MS detecting and biomarkers models as diagnosing NSCLC. Considering the fact that different thresholds may occur across studies and it is clinically unhelpful, we didn't estimate summary sensitivity and specificity by pooling studies with varying cut-off values, but illustrated individual sensitivity and specificity by range of plots. We also extracted and calculated sensitivity and specificity from each study and presented the data as DOR and summary receiver operating characteristic (SROC) curves to illustrate the performance of diagnosis models with SELDI-TOF-MS as identifying NSCLC using the area under the curve (AUC) value. We used Meta-Disc1.4 software to analyse the plots and curve.
Results
The literature search yielded 467 citations, of which 138 were excluded for duplicates. 210 publications were excluded because they failed to meet the eligible criteria on the basis of title and abstract. Of the 119 potentially Table I . studies (n 5 5), no diagnostic value studies (n 5 30) and unable to extract data (n 5 43). Finally, 11 focused on the target patient spectrum were included (Figure 1 ). Table II described the general characteristics of the included studies. As regards patient samples, one study was tissue sample (TS) (20) . Two studies were related to cerebrospinal fluid (CSF) (21, 22) . One article failed to describe age groups (23) . We constructed diagnosis values of the patient population as a 2 3 2 table (Table III) by methods for diagnostic meta-analysis (24, 25) .
The ranges of SEN and SPE of diagnosis model with SELDI-TOF-MS as identifying of NSCLC were 0.701.00 ( Figure 2 ) and 0.681.00 (Figure 3 ), respectively. The SROC curve represented the relationship between SEN and SPE across studies, recognizing that different thresholds may have been used. With an overall AUC value of SROC curve was 0.9380 ( Figure 4 ). The ranges of PLR ( Figure 5 ) and NLR ( Figure 6 ) were 2.2323.14 and 0.040.43, respectively. The range of DOR was 5.17621.00 ( Figure 7) .
All of the studies were free of commercial funding and provided a clear definition of what was considered to be a 'positive' result and the technology of the index test was unchanged since the study was carried out. The cut off value depended on different statistic algorithm. Liao (26) study involved in statistic algorithm was SPSS 13.0, and studies of Yang (20) and Yang (17) were support vector machine (SVM). Remains were decision tree classification. All studies were pre-specified objectively. Data on instrument variation were reported and within an acceptable range and data then, the specificity remained low (53%) at a sensitivity of 86%. Thus the application of new technologies for the earlier detection of NSCLC could have an important role in public health. To achieve this goal, specific and sensitive molecular markers are essential.
As a new technique of research proteomics, SELDI-TOF-MS was firstly introduced in 1993 and was commercialized by Ciphergen Biosystems in 1997 as the ProteinChip system (36) . It is noted that SELDI-TOF-MS can also contribute to the ongoing human proteome studies, as proposed for the total proteins in the serum and other samples. SELDI-TOF-MS based protein profiling has been successfully applied in identification of different cancers and cancer-related biomarkers in diverse diagnostic samples as serum, plasma and tissue biopsies (20) . When combined with radiological data, SELDI may bring patients new hopes in the early detection of NSCLC inside even before the onset of symptoms.
When we selected studies, no matter how many chip types, samples and algorithms were, if the study design was in line with the theme subjects, we would accept it. Data extraction was the key point of systematic review, accordingly, every paper should get some quantification parameters such as numbers of testing set/group, sensitivity and specificity, with which we could construct a 2 3 2 table (Table III) . In Table III , two studies' (21, 22) sample was cerebrospinal fluid, accordingly, cerebrospinal fluid may express less proteins. Conversely, Yang (20) researched protein profiles of tissue samples using laser capture micro dissection (LCM), and high values (sensitivity 100% and specificity 100%) were obtained. In Monari's (1) paper, two chips detected biomarkers and built different diagnosis model with low values. Different sample types, chip types and data algorithms would make difference of clinical or methodological homogeneity significant. All of these could affect diagnosis values and be source of heterogeneity, so we chose ranges rather than pooling to evaluate values of diagnosis.
We analyzed all included data to draw plots, and they showed the ranges of sensitivity and specificity of diagnosis model with SELDI-TOF-MS as identifying of NSCLC were 0.701.00 and 0.681.00, respectively. With an overall AUC value of SROC curve was 0.9380. The ranges of positive likelihood ratio and negative likelihood ratio were 2.2323.14 and 0.040.43, respectively. The range of diagnostic odds ratio was 5.17621.00. It proved these studies used SELDI-TOF-MS detecting biomarkers and establishing model to diagnose NSCLC possessed potentially high diagnosis values. These preliminary results suggested SELDI-TO-MS was a valuable method for diagnosing and identifying NSCLC.
For potential additional quality items, diagnosis was established using path morphological or other evidence to confirm.
on observer variation were not available. All papers didn't describe whether test operators had appropriate training. Seven studies clearly pointed out that treatment was withheld until both the index test and reference standard were performed except Xiao (23), Yang (27) , Yang (17) and Liao (26) which were not available.
Discussion
Recently, many efforts have been made to improve the percentage of diagnosis at early stage, as CT scans, bronchoscope and sputum analysis have proved to be inadequate screening tests. CT screening for lung cancer is a complex and controversial topic. CT scan offers great anatomical detail of tumor spread, but the high false positive rate of 96.4% observed in the low dose CT group is likely to hinder the adoption of CT scans in population screening. In addition, questions about the cost-effectiveness of CT-based screening for lung cancer remain unanswered. Also, there is some concern that repeated exposure to low dose CT scans may expose patients to potentially harmful levels of radiation that could result in more cancers (31) . Overall, the pooled sensitivity and specificity of CT for identifying mediastinal LN metastasis are 51% [95% confidence interval (CI) 47% to 54%] and 85% (95% CI 84% to 88%), respectively (32) . Bronchoscope is the most widely used tool for diagnosis of NSCLC, but two thirds of the light-induced fluorescence endoscope (LIFE)-detected suggestive lesions are false positive after correlation with pathology. Because of this, low-specificity LIFE cannot be used as a screening tool (33) . Though by using this narrow-band bronchoscopic technique, a higher specificity can be achieved up to 80% without significantly compromising the sensitivity, the interpretation is complex, and the scopist must know the characteristics of premalignant lesions. Bronchoscopy couldn't yet play a role for early diagnosis NSCLC (33) . There are no specific blood tumor markers for clinical diagnosis of PLC at the present. A number of potential biomarkers have been identified, such as carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1), neuron-specific enolase (NSE), and cancer antigen-125 (CA-125). However, none of these biomarkers are ideal early detection markers because of their low specificity and/or sensitivity (4 However, for prospective studies, SELDI-TOF-MS experiments are described presenting their respective advantages and limitations. Many reviews drove validation of these biomarkers quite challenging (6, 37) . All challenges that should be undertaken to avoid any bias, to maximize reproducibility and detection sensitivity, with the final aim to find relevant, specific, and robust biomarkers are addressed (6) . For prospective studies, current knowledge on the different biological fluid sources available for SELDI-TOF-MS experiments is described presenting their respective advantages and limitations. Because of its advantages, lots of applications about SELDI-TOF-MS in the globe have emerged during short period. Also because of its challenges, many recent reviews discussed the perspective of its development and the reproducibility of detecting results (38) . To face the general criticism, standardized procedures and recommendations to minimize bias are now followed by most of the users. Based on these debates, we chose values of non-small cell lung cancer' diagnosis with SELDI-TOF-MS to review the accuracy of these diagnostic models, and approached some factors affecting the results. Many manuscripts report encountered problems, emphasizing the importance of standard operating procedures (SOPs), clinical protocols, instrument tuning, and stabilization (38) . In short, Interaction between researchers, clinicians, and statisticians is also a key element for the success. If we could face the challenge rationality, we believe that SELDI-TOF-MS will become one of the most powerful tools in early cancer diagnosis in coming days.
Conclusion
In conclusion, this systematic review suggests that the SELDI-TOF-MS is a potential method to diagnose NSCLC, but it must overcome some variable factors.
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